• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

    2/23/22 4:29:11 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HOTH alert in real time by email
    SC 13G/A 1 c103098_sc13ga.htm
     
         
      SECURITIES AND EXCHANGE
    COMMISSION
     
      Washington, D.C. 20549  

     

     

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2.

     

    (Amendment No. 1)*

     

    Hoth Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    44148G105

    (CUSIP Number)

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    o Rule 13d-1(b)
       
    x Rule 13d-1(c)
       
    o Rule 13d-1(d)

     

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

      CUSIP No: 44148G105
      (1) Names of Reporting Persons
    Iroquois Capital Management L.L.C.
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o        
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6)

    Shared Voting Power

    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

     
    (7) Sole Dispositive Power
    0
     
    (8)

    Shared Dispositive Power

    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    3.66%
      (12) Type of Reporting Person (See Instructions)
    OO

     

    CUSIP No: 44148G105
      (1) Names of Reporting Persons
    Richard Abbe
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o        
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5)

    Sole Voting Power


    354,430 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     
    (6) Shared Voting Power

    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    (7) Sole Dispositive Power
    354,430 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*
     
    (8) Shared Dispositive Power

    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

      (9)

    Aggregate Amount Beneficially Owned by Each Reporting Person

    1,265,822 shares of Common Stock issuable upon exercise of Warrants (See Item 4)*

     

      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    4.99%
      (12) Type of Reporting Person (See Instructions)
    IN; HC

     

     * As more fully described in Item 4, the Warrants are subject to a 4.99% blocker and the percentage set forth in row (11) gives effect to such blocker. However, as more fully described in Item 4, the securities reported in rows (6), (8) and (9) show the number of shares of Common Stock that would be issuable upon full exercise of such reported securities and do not give effect to such blocker. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blocker, is less than the number of securities reported in rows (6), (8) and (9).

     
     
     CUSIP No: 44148G105
      (1) Names of Reporting Persons
    Kimberly Page
      (2) Check the Appropriate Box if a Member of a Group (See Instructions)
        (a) o        
        (b) o
      (3) SEC Use Only
      (4) Citizenship or Place of Organization
    United States of America

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    (5) Sole Voting Power
    0
     
    (6) Shared Voting Power

    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)
     
    (7) Sole Dispositive Power
    0
     
    (8) Shared Dispositive Power
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

      (9) Aggregate Amount Beneficially Owned by Each Reporting Person
    911,392 shares of Common Stock issuable upon exercise of Warrants (See Item 4)
      (10) Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  o
      (11) Percent of Class Represented by Amount in Row (9)
    3.66%
      (12) Type of Reporting Person (See Instructions)
    IN
     

    CUSIP No: 44148G105

     

     

    This Amendment No. 1 (this “Amendment”) amends the statement on Schedule 13G filed on March 18, 2021 (the “Original Schedule 13G”) with respect to the Common Stock, $0.0001 par value (the “Common Stock”) of Hoth Therapeutics, Inc., a Nevada corporation (the “Company”). Capitalized terms used herein and not otherwise defined in this Amendment have the meanings set forth in the Original Schedule 13G. This Amendment amends and restates each of Item 4 and Item 5 in its entirety as set forth below.

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 23,974,178 shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed with the U.S. Securities and Exchange Commission on November 10, 2021, and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”) subject to the Blocker (as defined below).

     

    Pursuant to the terms of the Reported Warrants, the Reporting Persons cannot exercise the Reported Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 4.99% of the outstanding shares of Common Stock (the “Blocker”), and the percentage set forth in Row 11 of the cover page for each Reporting Person gives effect to the Blocker.

     

    As of the date of the event which requires filing of this statement, Iroquois Master Fund Ltd. (“Iroquois Master Fund”) held Reported Warrants to purchase 911,392 shares of Common Stock (subject to the Blocker) and Iroquois Capital Investment Group LLC (“ICIG”) held Reported Warrants to purchase 354,430 shares of Common Stock (subject to the Blocker).

     

    Mr. Abbe shares authority and responsibility for the investments made on behalf of Iroquois Master Fund with Ms. Kimberly Page, each of whom is a director of the Iroquois Master Fund. As such, Mr. Abbe and Ms. Page may each be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants (each subject to the Blocker) held by Iroquois Master Fund. Iroquois Capital is the investment advisor for Iroquois Master Fund and Mr. Abbe is the President of Iroquois Capital. Mr. Abbe has the sole authority and responsibility for the investments made on behalf of ICIG. As such, Mr. Abbe may be deemed to be the beneficial owner of all shares of Common Stock underlying the Reported Warrants (each subject to the Blocker) held by Iroquois Master Fund and ICIG. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person. Each of the Reporting Persons hereby disclaims any beneficial ownership of any such shares of Common Stock except to the extent of their pecuniary interest therein.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following:   x

     

    Item 10. Certification

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 22, 2022

     

      IROQUOIS CAPITAL MANAGEMENT L.L.C.  
           
      By:     /s/  Richard Abbe  
          Richard Abbe, President  
           
        /s/ Richard Abbe  
      Richard Abbe  
           
        /s/ Kimberly Page  
      Kimberly Page  

     
    Get the next $HOTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HOTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HOTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform

      Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a clinical-stage biopharmaceutical company developing next-generation RNA-targeted precision therapies, today announced it has been granted a key patent by the Japan Patent Office (JPO), expanding its global intellectual property portfolio in RNA-based cancer therapeutics. The newly issued patent secures broad claims covering antisense oligome

      4/17/25 8:01:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial

      Reports 50% Reduction in Pruritus (Mean Score Dropped from 1.6 to 0.8) by Day 21 inOpen-Label Portion of CLEER HT-001 Phase 2a clinical Trial for Cancer EGFR Inhibitor-Induced Skin Toxicities Key Interim Results (Day 1–21): Patients experienced a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21.Rapid symptom relief was observed, with mean scores improving to 1.0 by Day 7.Some patients achieved complete resolution of pruritus within the 21-day period.HT-001 was well tolerated, with no treatment-related serious adverse events reported.NEW YORK, April 15, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc.(NASDAQ:HOTH), a biopharmaceutical company focuse

      4/15/25 8:19:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

      NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced its collaboration with Washington University School of Medicine in St. Louis to advance Alzheimer's disease research through a novel therapeutic strategy. The partnership centers on a recently submitted NIH grant proposal focused on studying HT-ALZ—an FDA-approved NK-1 receptor antagonist—for its potential to reduce neuroinflammation and improve cognitive function in Alzheimer's disease (AD). The research collaboration is le

      4/2/25 8:02:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CEO and President Knie Robb

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:55 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Springer Graig

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      1/15/25 4:15:06 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sarnoff David

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/21/24 4:15:05 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and President Knie Robb bought $16,750 worth of shares (25,000 units at $0.67), increasing direct ownership by 75% to 58,131 units (SEC Form 4)

      4 - Hoth Therapeutics, Inc. (0001711786) (Issuer)

      8/19/24 8:00:03 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    SEC Filings

    See more
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      5/2/25 8:20:24 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hoth Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      4/15/25 8:25:26 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Hoth Therapeutics Inc.

      10-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

      3/28/25 4:15:47 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Hoth Therapeutics Announces the Appointment of John Cirrito, PhD and Carla Yuede, PhD to Oversee Alzheimer's Therapeutic Program as Part of Hoth Scientific Advisory Board

      NEW YORK, Jan. 31, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, today announced the addition of John Cirrito, PhD and Carla Yuede, PhD to the Company's Scientific Advisory Board. While serving on the Board, Dr. Cirrito and Dr. Yuede will oversee the development of HT-ALZ, an oral therapeutic in development under the 505(b)(2) regulatory pathway for the treatment of Alzheimer's disease (AD) and symptoms associated with AD. Mr. Robb Knie, CEO of Hoth Therapeutics, commented, "Hoth is extremely pleased to welcome Dr. Cir

      1/31/22 8:17:00 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HOTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/24 2:47:32 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Hoth Therapeutics Inc.

      SC 13G - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/14/23 12:55:35 PM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Hoth Therapeutics Inc. (Amendment)

      SC 13G/A - Hoth Therapeutics, Inc. (0001711786) (Subject)

      2/8/23 6:07:04 AM ET
      $HOTH
      Biotechnology: Pharmaceutical Preparations
      Health Care